Nemes Laszlo/iStock via Getty Images
Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed initial results from a Phase 3 trial for the protein degrader on Tuesday.
According to the companies, the trial named VERITAC-2 reached the primary endpoint